With com­pe­ti­tion on its heels, Blue­print takes three can­cer drugs to Chi­na

Blue­print Med­i­cines $BPMC is cash­ing in on the chance to take three of its in­ves­ti­ga­tion­al can­cer ther­a­pies to Chi­na, ink­ing a deal with CStone Phar­ma­ceu­ti­cals that gives the Shang­hai-based com­pa­ny rights to de­vel­op and com­mer­cial­ize the drugs re­gion­al­ly.

The deal gets Blue­print an up­front pay­ment of $40 mil­lion, along with $346 mil­lion in po­ten­tial mile­stones. CStone gets the OK to de­vel­op and sell the meds in Chi­na, Hong Kong, Macau, and Tai­wan — both as stand­alone ther­a­pies or com­bos.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER